Alpha Genesis Launches AGI Ventures with an Initial $50 Million Commitment to Emerging Biotechnology CompaniesNew venture-development division pairs strategic investment with the scientific expertise and preclinical research infrastructure of Alpha Genesis
Alpha Genesis Adds Rodent Studies, Creating an Integrated Rodent-to-Primate Preclinical PlatformNew capability lets sponsors run programs from early rodent proof-of-concept through advanced nonhuman-primate translational studies with a single AAALAC-accredited, USDA-licensed partner.
